Covered recipient · General Payments record
NELIA ESTHER SANCHEZ-CRESPO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$252.44
16 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $252.44 | 16 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $84.94 | 6 |
| PFIZER INC. | $66.08 | 4 |
| Novartis Pharmaceuticals Corporation | $33.67 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.97 | 2 |
| Novo Nordisk Inc | $24.45 | 1 |
| AstraZeneca Pharmaceuticals LP | $14.33 | 1 |
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NELIA ESTHER SANCHEZ-CRESPO
NPI 1790990851 · CMS profile ID 699626
Allopathic & Osteopathic Physicians / Internal Medicine
HOLLYWOOD, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
16 matching records · $252.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–16 of 16.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $24.45 | 10/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811113163 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.78 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763425646 | CMS |
| Novartis Pharmaceuticals Corporation | $17.42 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813227533 | CMS |
| PFIZER INC. | $14.77 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833381621 | CMS |
| PFIZER INC. | $17.63 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832567061 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.19 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763425648 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.33 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834352719 | CMS |
| Lilly USA, LLC | $15.96 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818660999 | CMS |
| Lilly USA, LLC | $15.18 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818614479 | CMS |
| PFIZER INC. | $19.86 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833487705 | CMS |
| Novartis Pharmaceuticals Corporation | $16.25 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813227529 | CMS |
| Lilly USA, LLC | $13.33 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818665389 | CMS |
| Lilly USA, LLC | $13.26 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818609677 | CMS |
| Lilly USA, LLC | $13.71 | 02/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818609675 | CMS |
| PFIZER INC. | $13.82 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833549405 | CMS |
| Lilly USA, LLC | $13.50 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818669367 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,652,523.02 | 227 |
| PY2024 | Principal investigator | $7,882,760.60 | 649 |
| PY2023 | Principal investigator | $10,990,435.50 | 4,306 |
| PY2022 | Principal investigator | $2,420,977.88 | 1,673 |
| PY2021 | Principal investigator | $723,239.31 | 8 |
| PY2020 | Principal investigator | $1,155,430.22 | 12 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
227 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $54,234.00 | 12/31/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228743904 |
| Principal investigator 1 | PFIZER INC. | $400,827.00 | 12/22/2025 | Non-covered Recipient Entity CenExel Hollywood FL | A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF 28 WEEKS TO INVESTIGATE THE SAFETY AND EFFICACY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT FOLLOWED BY A 32WEEK EXTENSION VESPER1 | No dispute reported | 06/30/2026 | 1228721389 |
| Principal investigator 1 | ModernaTX, Inc. | $520.00 | 12/15/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252985148 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 12/11/2025 | Non-covered Recipient Entity CLINICAL BIOSAFETY SERVICES LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985054 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $445.50 | 12/05/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115596 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $29,601.00 | 12/01/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115591 |
| Principal investigator 1 | ModernaTX, Inc. | $66,330.00 | 11/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985070 |
| Principal investigator 1 | ModernaTX, Inc. | $5,394.60 | 11/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985120 |
| Principal investigator 1 | ModernaTX, Inc. | $3,199.50 | 11/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985188 |
| Principal investigator 1 | ModernaTX, Inc. | $12,909.60 | 11/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985210 |
| Principal investigator 1 | ModernaTX, Inc. | $1,472.00 | 11/20/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008554 |
| Principal investigator 1 | ModernaTX, Inc. | $3,500.00 | 11/20/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008556 |
| Principal investigator 1 | ModernaTX, Inc. | $1,900.00 | 11/20/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008566 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985196 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,299.30 | 11/07/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115573 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,263.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509337 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $207.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509343 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $854.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509347 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $810.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509351 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $518.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509355 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $38.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509359 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,835.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509363 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,384.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509366 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,110.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509371 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,470.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509375 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,654.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509378 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,562.00 | 11/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509382 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 11/06/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985194 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/06/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008540 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 11/06/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008550 |
| Principal investigator 1 | ModernaTX, Inc. | $3,120.00 | 10/29/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985106 |
| Principal investigator 1 | ModernaTX, Inc. | $2,925.00 | 10/29/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985178 |
| Principal investigator 1 | ModernaTX, Inc. | $5,850.00 | 10/29/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985206 |
| Principal investigator 1 | ModernaTX, Inc. | $23,463.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985064 |
| Principal investigator 1 | ModernaTX, Inc. | $10,189.80 | 10/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985132 |
| Principal investigator 1 | ModernaTX, Inc. | $4,449.60 | 10/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985154 |
| Principal investigator 1 | ModernaTX, Inc. | $10,692.00 | 10/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985160 |
| Principal investigator 1 | ModernaTX, Inc. | $2,381.40 | 10/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985192 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008560 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $375.00 | 10/27/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115560 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 10/27/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115584 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 10/24/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252985090 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $12,566.00 | 10/23/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215509340 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $54,708.75 | 10/15/2025 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226095697 |
| Principal investigator 1 | PFIZER INC. | $55,296.00 | 10/11/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228756549 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 10/03/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008570 |
| Principal investigator 1 | ModernaTX, Inc. | $5,694.30 | 09/29/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985128 |
| Principal investigator 1 | ModernaTX, Inc. | $12,335.40 | 09/29/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985164 |
| Principal investigator 1 | PFIZER INC. | $12,256.18 | 09/16/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228752215 |
| Principal investigator 1 | ModernaTX, Inc. | $10,400.00 | 09/11/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252985092 |
| Principal investigator 1 | ModernaTX, Inc. | $154.14 | 09/03/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985050 |
| Principal investigator 1 | ModernaTX, Inc. | $194.40 | 09/03/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985098 |
| Principal investigator 1 | PFIZER INC. | $35,188.16 | 09/03/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228750016 |
| Principal investigator 1 | PFIZER INC. | $9,232.64 | 09/03/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228761378 |
| Principal investigator 1 | ModernaTX, Inc. | $11,444.40 | 08/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985072 |
| Principal investigator 1 | ModernaTX, Inc. | $21,278.70 | 08/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985122 |
| Principal investigator 1 | ModernaTX, Inc. | $24,750.00 | 08/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985156 |
| Principal investigator 1 | ModernaTX, Inc. | $650.70 | 08/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985170 |
| Principal investigator 1 | ModernaTX, Inc. | $118.56 | 08/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008568 |
| Principal investigator 1 | ModernaTX, Inc. | $3,250.00 | 08/20/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985094 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,500.00 | 08/15/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506533 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 08/15/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506537 |
| Principal investigator 1 | PFIZER INC. | $16,964.15 | 08/14/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767842 |
| Principal investigator 1 | ModernaTX, Inc. | $260.00 | 07/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252985048 |
| Principal investigator 1 | ModernaTX, Inc. | $1,340.00 | 07/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985088 |
| Principal investigator 1 | ModernaTX, Inc. | $2,692.80 | 07/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985138 |
| Principal investigator 1 | ModernaTX, Inc. | $599.40 | 07/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985176 |
| Principal investigator 1 | ModernaTX, Inc. | $650.70 | 07/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985216 |
| Principal investigator 1 | ModernaTX, Inc. | $54,340.00 | 07/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008538 |
| Principal investigator 1 | PFIZER INC. | $14,845.35 | 07/25/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228772710 |
| Principal investigator 1 | ModernaTX, Inc. | $324.00 | 07/23/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985058 |
| Principal investigator 1 | ModernaTX, Inc. | $908.79 | 07/23/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985060 |
| Principal investigator 1 | ModernaTX, Inc. | $388.80 | 07/23/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985062 |
| Principal investigator 1 | ModernaTX, Inc. | $754.65 | 07/23/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985150 |
| Principal investigator 1 | ModernaTX, Inc. | $517.14 | 07/23/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985152 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,511.05 | 07/18/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1192143911 |
| Principal investigator 1 | PFIZER INC. | $1,979.38 | 07/16/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228764333 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $460.35 | 07/14/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506544 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $47.25 | 07/14/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506549 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $26,106.80 | 07/14/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506554 |
| Principal investigator 1 | PFIZER INC. | $12,779.20 | 07/11/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228764345 |
| Principal investigator 1 | PFIZER INC. | $5,605.20 | 07/11/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228772366 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17,450.90 | 07/02/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506540 |
| Principal investigator 1 | ModernaTX, Inc. | $7,623.00 | 06/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985162 |
| Principal investigator 1 | ModernaTX, Inc. | $28,710.00 | 06/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985174 |
| Principal investigator 1 | ModernaTX, Inc. | $8,691.30 | 06/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985180 |
| Principal investigator 1 | PFIZER INC. | $14,352.48 | 06/26/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228777323 |
| Principal investigator 1 | PFIZER INC. | $33,067.09 | 06/26/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228790743 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,499.00 | 06/25/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506522 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506525 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 06/25/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506529 |
| Principal investigator 1 | ModernaTX, Inc. | $7,265.96 | 06/18/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985052 |
| Principal investigator 1 | ModernaTX, Inc. | $18,281.70 | 06/18/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985100 |
| Principal investigator 1 | ModernaTX, Inc. | $42,570.00 | 06/18/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985108 |
| Principal investigator 1 | ModernaTX, Inc. | $10,810.80 | 06/18/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985112 |
| Principal investigator 1 | ModernaTX, Inc. | $8,532.00 | 06/18/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985190 |
| Principal investigator 1 | ModernaTX, Inc. | $4,145.94 | 06/18/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008544 |
| Principal investigator 1 | PFIZER INC. | $5,938.14 | 06/14/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228774836 |
| Principal investigator 1 | PFIZER INC. | $13,700.00 | 06/11/2025 | Non-covered Recipient Entity CenExel Clinical Research INC | A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228789878 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $70,762.20 | 06/11/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115564 |
| Principal investigator 1 | PFIZER INC. | $267,212.75 | 05/30/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228762584 |
| Principal investigator 1 | ModernaTX, Inc. | $20,379.60 | 05/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985102 |
| Principal investigator 1 | ModernaTX, Inc. | $48,510.00 | 05/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985118 |
| Principal investigator 1 | ModernaTX, Inc. | $8,454.60 | 05/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985168 |
| Principal investigator 1 | ModernaTX, Inc. | $23,493.66 | 05/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008572 |
| Principal investigator 1 | PFIZER INC. | $989.69 | 05/23/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228773242 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,500.00 | 05/22/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190308772 |
| Principal investigator 1 | PFIZER INC. | $34,794.00 | 05/16/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228762933 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 05/14/2025 | Non-covered Recipient Entity CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985110 |
| Principal investigator 1 | ModernaTX, Inc. | $875.00 | 05/14/2025 | Non-covered Recipient Entity CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985124 |
| Principal investigator 1 | PFIZER INC. | $12,930.97 | 05/14/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763430 |
| Principal investigator 1 | PFIZER INC. | $244.72 | 05/14/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228782058 |
| Principal investigator 1 | ModernaTX, Inc. | $10,862.00 | 05/07/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985208 |
| Principal investigator 1 | PFIZER INC. | $362.34 | 05/07/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228773926 |
| Principal investigator 1 | PFIZER INC. | $599,761.54 | 05/06/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228773769 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,670.00 | 05/06/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115534 |
| Principal investigator 1 | PFIZER INC. | $128,453.75 | 04/29/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228796250 |
| Principal investigator 1 | ModernaTX, Inc. | $7,365.60 | 04/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985074 |
| Principal investigator 1 | ModernaTX, Inc. | $1,301.40 | 04/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985116 |
| Principal investigator 1 | ModernaTX, Inc. | $48,551.40 | 04/28/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985200 |
| Principal investigator 1 | ModernaTX, Inc. | $3,685.28 | 04/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008548 |
| Principal investigator 1 | ModernaTX, Inc. | $3,043.04 | 04/28/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008562 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $24,960.96 | 04/28/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115548 |
| Principal investigator 1 | PFIZER INC. | $772.22 | 04/25/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228779628 |
| Principal investigator 1 | Mylan Technologies Inc. | $230,210.50 | 04/22/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety | No dispute reported | 06/30/2026 | 1241759915 |
| Principal investigator 1 | ModernaTX, Inc. | $36.50 | 04/17/2025 | Non-covered Recipient Entity Research Centers of America | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985096 |
| Principal investigator 1 | ModernaTX, Inc. | $89.10 | 04/09/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985044 |
| Principal investigator 1 | ModernaTX, Inc. | $154.14 | 04/09/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985142 |
| Principal investigator 1 | ModernaTX, Inc. | $137.70 | 04/09/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985144 |
| Principal investigator 1 | ModernaTX, Inc. | $388.80 | 04/09/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985184 |
| Principal investigator 1 | PFIZER INC. | $5,168.00 | 04/08/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228778827 |
| Principal investigator 1 | PFIZER INC. | $48,561.43 | 04/08/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228793692 |
| Principal investigator 1 | PFIZER INC. | $9,152.75 | 04/05/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228781080 |
| Principal investigator 1 | ModernaTX, Inc. | $99.78 | 04/04/2025 | Non-covered Recipient Entity Research Centers of America | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985198 |
| Principal investigator 1 | PFIZER INC. | $6,691.97 | 03/28/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228789151 |
| Principal investigator 1 | ModernaTX, Inc. | $3,151.80 | 03/24/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985068 |
| Principal investigator 1 | ModernaTX, Inc. | $27,720.00 | 03/24/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985114 |
| Principal investigator 1 | ModernaTX, Inc. | $7,048.80 | 03/24/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985136 |
| Principal investigator 1 | ModernaTX, Inc. | $39,260.70 | 03/24/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985204 |
| Principal investigator 1 | ModernaTX, Inc. | $11,516.50 | 03/24/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008534 |
| Principal investigator 1 | ModernaTX, Inc. | $5,451.28 | 03/24/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008536 |
| Principal investigator 1 | PFIZER INC. | $69,707.62 | 03/22/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779888 |
| Principal investigator 1 | PFIZER INC. | $12,050.00 | 03/22/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228783922 |
| Principal investigator 1 | PFIZER INC. | $120,621.28 | 03/22/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228789697 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $78,450.48 | 03/18/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190310486 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,101.56 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1192143906 |
| Principal investigator 1 | ModernaTX, Inc. | $6,000.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985082 |
| Principal investigator 1 | ModernaTX, Inc. | $6,360.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985140 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985182 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985218 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985224 |
| Principal investigator 1 | ModernaTX, Inc. | $8,000.00 | 03/12/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985226 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 03/10/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985220 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 03/10/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of Modified mRNA Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985222 |
| Principal investigator 1 | Mylan Technologies Inc. | $235,499.50 | 03/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety | No dispute reported | 06/30/2026 | 1241759909 |
| Principal investigator 1 | Mylan Technologies Inc. | $4,000.00 | 03/06/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety | No dispute reported | 06/30/2026 | 1241759913 |
| Principal investigator 1 | PFIZER INC. | $32,889.70 | 03/04/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228719749 |
| Principal investigator 1 | PFIZER INC. | $176,715.47 | 03/04/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723014 |
| Principal investigator 1 | ModernaTX, Inc. | $29,440.80 | 02/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252985056 |
| Principal investigator 1 | ModernaTX, Inc. | $9,761.40 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985080 |
| Principal investigator 1 | ModernaTX, Inc. | $35,664.30 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985134 |
| Principal investigator 1 | ModernaTX, Inc. | $88,250.40 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985166 |
| Principal investigator 1 | ModernaTX, Inc. | $33,660.00 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985172 |
| Principal investigator 1 | ModernaTX, Inc. | $2,602.80 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985212 |
| Principal investigator 1 | ModernaTX, Inc. | $7,603.20 | 02/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985214 |
| Principal investigator 1 | ModernaTX, Inc. | $4,606.60 | 02/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008542 |
| Principal investigator 1 | ModernaTX, Inc. | $2,136.56 | 02/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008546 |
| Principal investigator 1 | ModernaTX, Inc. | $1,547.00 | 02/26/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008564 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $10,000.00 | 02/25/2025 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215506496 |
| Principal investigator 1 | PFIZER INC. | $4,359.10 | 02/22/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228751710 |
| Principal investigator 1 | PFIZER INC. | $10.34 | 02/21/2025 | Non-covered Recipient Entity Research Centers of America Hollywood | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228771191 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,670.00 | 02/21/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115654 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $21,568.04 | 02/21/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115660 |
| Principal investigator 1 | PFIZER INC. | $815,458.80 | 02/19/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228750495 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,292.50 | 02/18/2025 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226095620 |
| Principal investigator 1 | PFIZER INC. | $34,305.07 | 02/14/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228720621 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $955.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506484 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506489 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506493 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $10,000.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506501 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,481.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506506 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $846.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506510 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,895.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506514 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,675.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215506517 |
| Principal investigator 1 | PFIZER INC. | $18,000.00 | 02/12/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228758694 |
| Principal investigator 1 | ModernaTX, Inc. | $1,687.50 | 02/05/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985042 |
| Principal investigator 1 | ModernaTX, Inc. | $5,058.00 | 02/05/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985086 |
| Principal investigator 1 | PFIZER INC. | $3,957.05 | 02/05/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228769336 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,320.00 | 02/05/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115618 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 02/05/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115623 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,750.00 | 02/05/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115629 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,670.00 | 02/05/2025 | Non-covered Recipient Entity Research Centers Of America | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115635 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 02/03/2025 | Non-covered Recipient Entity Research Centers Of America | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226115609 |
| Principal investigator 1 | ModernaTX, Inc. | $6,414.12 | 01/30/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252985046 |
| Principal investigator 1 | ModernaTX, Inc. | $31,168.80 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985066 |
| Principal investigator 1 | ModernaTX, Inc. | $2,602.80 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985076 |
| Principal investigator 1 | ModernaTX, Inc. | $6,930.00 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985078 |
| Principal investigator 1 | ModernaTX, Inc. | $4,059.00 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985104 |
| Principal investigator 1 | ModernaTX, Inc. | $6,098.40 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985158 |
| Principal investigator 1 | ModernaTX, Inc. | $53,580.60 | 01/27/2025 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985202 |
| Principal investigator 1 | ModernaTX, Inc. | $6,909.90 | 01/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008532 |
| Principal investigator 1 | ModernaTX, Inc. | $1,521.52 | 01/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008552 |
| Principal investigator 1 | ModernaTX, Inc. | $6,409.68 | 01/27/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008558 |
| Principal investigator 1 | PFIZER INC. | $2,079.27 | 01/25/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228798251 |
| Principal investigator 1 | PFIZER INC. | $20,569.00 | 01/25/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798951 |
| Principal investigator 1 | PFIZER INC. | $17,623.39 | 01/24/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228802013 |
| Principal investigator 1 | PFIZER INC. | $1,534.00 | 01/23/2025 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707165 |
| Principal investigator 1 | PFIZER INC. | $1,534.00 | 01/23/2025 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228771513 |
| Principal investigator 1 | ModernaTX, Inc. | $17,973.90 | 01/22/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985038 |
| Principal investigator 1 | ModernaTX, Inc. | $26,766.45 | 01/22/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985040 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $315,326.25 | 01/21/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226115667 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $380.00 | 01/20/2025 | Non-covered Recipient Entity Research Centers Of America | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115647 |
| Principal investigator 1 | ModernaTX, Inc. | $1,308.15 | 01/17/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985084 |
| Principal investigator 1 | ModernaTX, Inc. | $453.60 | 01/17/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985146 |
| Principal investigator 1 | ModernaTX, Inc. | $344.30 | 01/17/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252985186 |
| Principal investigator 1 | PFIZER INC. | $1,534.00 | 01/15/2025 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707167 |
| Principal investigator 1 | PFIZER INC. | $1,534.00 | 01/15/2025 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228761354 |
| Principal investigator 1 | PFIZER INC. | $38,179.06 | 01/15/2025 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228800416 |
| Principal investigator 1 | PFIZER INC. | $2,772.36 | 01/15/2025 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228801842 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 01/14/2025 | Non-covered Recipient Entity Research Centers of America | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985126 |
| Principal investigator 1 | Mylan Technologies Inc. | $6,000.00 | 01/10/2025 | Non-covered Recipient Entity Research Centers of America, LLC | A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety | No dispute reported | 06/30/2026 | 1241759911 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,355.12 | 01/10/2025 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226095614 |
| Principal investigator 1 | ModernaTX, Inc. | $199.56 | 01/06/2025 | Non-covered Recipient Entity Research Centers of America | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252985130 |
| Principal investigator 1 | ABBVIE INC. | $14,700.00 | 01/03/2025 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LL | Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202436653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,200.00 | 01/02/2025 | Non-covered Recipient Entity Research Centers Of America | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220663346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,750.00 | 01/02/2025 | Non-covered Recipient Entity Research Centers Of America | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220663348 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $375.00 | 01/02/2025 | Non-covered Recipient Entity Research Centers Of America | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220663350 |